Shanghai Model Organisms Center (USA), LLC

What Shanghai Model Organisms Center (USA), LLC does

Shanghai Model Organisms Center (USA), LLC (SMOC) is the U.S. commercial entity of Shanghai Model Organisms (南模生物), a biotechnology company founded in 2000 in Shanghai, China, and publicly listed on the Shanghai Stock Exchange STAR Market under stock code 688265. SMOC designs, generates, and supplies genetically engineered mouse and rat models using CRISPR/Cas9 gene editing and embryonic stem (ES) cell-based targeting technologies, supporting a catalog of nearly 10,000 standardized models and cell lines and more than 18,000 cumulative custom models developed since inception. Its product portfolio spans U-GEMMs, therapeutic target-humanized mice (covering PD-1, PD-L1, CTLA-4, CD47, TIGIT and other immune checkpoints), immunodeficient NMG mice, Cre/Dre-driver lines, disease models across oncology, metabolic, inflammatory, and neurological indications, and standardized cell lines. The company's proprietary U-HuDTMbase® library contains 600+ therapeutic target-humanized mouse models, and its SmartEddi AI-powered system accelerates the design of custom model schemes.

Beyond model supply, SMOC operates preclinical CRO service platforms spanning oncology drug efficacy evaluation (syngeneic, GMM, CDX/PDX, and human immune system reconstituted models), metabolism disease evaluation, inflammation/autoimmune disease evaluation, neurological disease evaluation, and toxicology/pathology services. Supporting offerings include colony management (cryopreservation, genotyping, breeding), surgery and preconditioning, pharmacology and pharmacokinetics, and ex vivo/in vitro evaluation. The U.S. LLC, headquartered in Sugar Land / Houston, Texas, executes a direct, enterprise sales-led go-to-market via website order forms, phone, and email, with quote-based, project-driven pricing and multi-language support (English, Chinese, Japanese, Korean). Its target customers are pharmaceutical and biotechnology companies, academic and research institutions, and contract research organizations across North America and globally. OLAW Animal Welfare Assurance approval and AAALAC accreditation provide the compliance credentials necessary for sales to U.S. federally funded and large-pharma preclinical programs.

Name

Shanghai Model Organisms Center (USA), LLC

Legal name

Shanghai Model Organisms Center (USA), LLC

Website

https://modelorg.us

Company type

Public

Founded year

2000

Operating status

Operating

Headcount range

1–10 employees

Short description

Shanghai Model Organisms Center (USA), LLC is the U.S. sales entity of Shanghai Model Organisms (SSE: 688265), supplying CRISPR- and ES cell-based genetically engineered mouse and rat models, the 600+ U-HuDTMbase® humanized model library, and preclinical CRO services to pharma, biotech, academic, and CRO customers in North America.

Ownership category

akta.pro rank

Product category

Preclinical Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)

akta.pro secondary industries

In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy) (HLAAAIAK), CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq) (HLAAAIAG), AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

Keywords

• Preclinical research services
• Genetically engineered mice
• Humanized mouse models
• Animal model services
• Immuno-oncology models

Headquarters

HQ city

Shanghai

HQ country

China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. Custom Genetically Engineered Model Generation: Custom generation of genetically engineered mice and rats using CRISPR/Cas9 and ES cell targeting technologies. Customers submit specifications and receive tailored animal models for their research needs.
2. Standardized Animal Models and Cell Lines: Sale of repository of nearly 10,000 standardized animal models and cell lines including humanized mice, immunodeficient mice, Cre/Dre-driver mice, reporter mice, disease models, and cell lines.
3. Preclinical CRO Services: Contract research services including pharmacology and pharmacokinetics studies, drug efficacy evaluation (oncology, metabolism, inflammation, neurological diseases), toxicology/pathology services, and behavioral research platforms.
4. Supporting Solutions: Colony management services including cryopreservation and cryorecovery, housing and management, genotyping analysis, breeding services, and auxiliary apparatus sales (e.g., e-BLOT WB Imaging System).

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Shanghai Model Organisms Center (USA), LLC generates, markets, and distributes genetically engineered mouse and rat models and cell lines, and provides preclinical contract research organization (CRO) services for drug discovery. Offerings span standardized catalog models, custom model generation via CRISPR/Cas9 and ES cell-based gene editing, therapeutic target-humanized mouse models organized within the U-HuDTMbase® library, immunodeficient NMG and Cre/Dre-driver strains, and integrated preclinical efficacy and safety evaluation platforms across oncology, metabolism, inflammation, neurological, and toxicology/pathology areas.

Product overview

Shanghai Model Organisms Center operates as a biotechnology company offering a comprehensive portfolio of genetically engineered animal models and preclinical CRO services. The core product portfolio includes U-GEMMs (Universal Genetically Engineered Mouse Models) with various categories: Therapeutic Target-Humanized Mice (humanized for tumor targets, immune checkpoints like PD-1/PD-L1/CTLA-4/CD47/TIGIT, cytokines, metabolic targets), Immunodeficient NMG Mice, Cre/Dre-Driver Mice, Disease Mouse Models (covering spontaneous tumors, rare diseases, infectious diseases, neurological diseases, cardio-metabolic diseases, autoimmune diseases), and Cell Lines. The company also provides specialized service platforms including Oncology Drug Efficacy Evaluation, Metabolism Disease Evaluation, Inflammation Disease Evaluation, Neurological Disease Evaluation, Toxicology/Pathology, and Cell Lines Service platforms. Supporting services include Custom Model Generation (powered by AI-driven SmartEddi system), Pharmacology and Pharmacokinetics Services, Colony Management, Surgery & Preconditioning, and Ex vivo/In vitro Evaluation. The company maintains a repository of nearly 10,000 standardized animal models and cell lines, and has developed more than 18,000 custom genetically engineered models for research and drug development since 2000.

Differentiator

Problem solved

Functional benefit

Brands

• U-HuDTMbase®: Inclusive Resource Library of Innovative Therapeutic Target-Humanized Mouse Models, composed of more than 600 therapeutic target-humanized mouse models to accelerate novel drug discovery.

Products and services

• U-GEMMs (Universal Genetically Engineered Mouse Models) Comprehensive toolbox of universal genetically engineered mouse models including conditional knockouts, knock-ins, and transgenic models for drug discovery research. Targeted at pharmaceutical and biotech drug discovery programs.
• Therapeutic Target-Humanized Mice Mouse models humanized for therapeutic drug targets including tumor targets, immune checkpoints (PD-1, PD-L1, CTLA-4, CD47, TIGIT), complements, cytokines, cytokine receptors, metabolic targets, and viral infection receptors. Used by immuno-oncology and drug discovery researchers.
• Immunodeficient NMG Mice Immunodeficient mouse strain suitable for human cell and tissue engraftment, used for oncology research and human immune system reconstitution studies. Targeted at researchers conducting xenograft and humanized immune system studies.
• Cre/Dre-Driver Mice Standardized portfolio of Cre/Dre-driver mice enabling conditional gene manipulation and recombination in vivo for genetic research. Targeted at researchers studying tissue-specific gene function.
• U-HuDTMbase® Inclusive resource library of more than 600 therapeutic target-humanized mouse models to accelerate novel drug discovery. Targeted at pharmaceutical and academic researchers working on immuno-oncology, rare diseases, and therapeutic target validation.
• Disease Mouse Models Genetically engineered mouse models for various diseases including spontaneous tumors, rare diseases, infectious diseases, nervous system diseases, cardio-metabolic diseases, and autoimmune diseases. Targeted at preclinical researchers across multiple therapeutic areas.
• Cell Lines Humanized mouse cell lines, reporter cell lines, and wild-type cell lines for generating xenograft tumor models and in vitro studies. Targeted at oncology and in vitro pharmacology researchers.
• Oncology Drug Efficacy Evaluation Platform Preclinical CRO platform providing syngeneic models, genetically modified tumor mouse models, xenograft models (CDX, PDX), and human immune system reconstituted models (HuPBMC, HuHSC) for oncology drug testing. Targeted at oncology drug developers and CRO partners.
• Metabolism Disease Evaluation Platform Platform for evaluating metabolism disease models including obesity/diabetes models, MASH model, hyperuricemia models, atherosclerosis models, phenylketonuria models, and humanized metabolic research models. Targeted at metabolic disease drug developers.
• Inflammation Disease Evaluation Platform Platform offering inflammation and autoimmune disease models including psoriasis, atopic dermatitis, asthma, rheumatoid arthritis, SLE, sepsis, MS, IBD, and other immune-mediated inflammatory disease models. Targeted at inflammation and immunology drug developers.
• Neurological Disease Evaluation Platform Platform providing neurological disease models including Parkinson's disease, Alzheimer's disease, depression, pain, cerebrovascular diseases, intracranial tumors, ALS models, and behavioral research services. Targeted at CNS drug developers.
• Toxicology/Pathology Service Platform Non-GLP toxicology evaluation platform and pathology service platform for preclinical safety assessment. Targeted at preclinical safety and regulatory scientists.
• Cell Lines Service Platform Platform offering off-the-shelf cell lines, iPSC-mediated disease models, and cell line customization services. Targeted at researchers requiring tailored cell line reagents.
• Custom Model Generation AI-powered custom model generation service using SmartEddi system for rapid generation of custom model schemes, supporting various genetic modifications including conventional knockout, conditional knockout, knock-in, point mutation, and humanization. Targeted at researchers with novel gene targets or specific genetic configurations.
• Pharmacology and Pharmacokinetics Services Wide-ranging animal model services for efficacy evaluation assays, pharmacodynamics studies, and safety assessment. Targeted at preclinical pharmacology teams.
• Colony Management Services Comprehensive colony management including cryopreservation and cryorecovery, housing and management, genotyping analysis, and breeding services. Targeted at academic and industry researchers maintaining animal colonies.
• Surgery & Preconditioning Services Surgical services and preconditioning for animal models to support preclinical research. Targeted at researchers requiring surgically prepared or conditioned animal models.
• Ex vivo & In vitro Evaluation Services Ex vivo and in vitro pharmacodynamic evaluation services for drug efficacy testing. Targeted at researchers complementing in vivo studies with ex vivo and in vitro assays.
• SmartEddi AI Model Design Platform AI-powered system for rapid generation of custom model schemes, helping to streamline the design and planning of genetically engineered animal models. Targeted at researchers specifying custom animal model projects.

Quantifiable outcome

• Repository of nearly 10,000 standardized animal models and cell lines for higher reproducibility and translatability
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature5 records

Partnerships

Three partnerships are on record, tiered core.

• Academic and Research InstitutionscoreOthersEstablished partnership with laboratories of universities and research institutes worldwide for genetic research and drug development collaboration.
• Pharmaceutical CompaniescoreStrategic or Co-development PartnerPartnership with some renowned pharmacy companies specializing in biotech-based drug research for custom model development and preclinical evaluation services.
• Contract Research Organizations (CROs)coreStrategic or Co-development PartnerEstablished partnership with CRO companies specializing in biotech-based drug research for collaborative preclinical development programs.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Peers

• GemPharmatech:

Broad incumbents

• The Jackson Laboratory: The leading U.S. provider of genetically engineered and humanized mouse models, with extensive disease model repositories and preclinical services. Directly comparable as a catalog model + custom generation peer, though much larger and more entrenched in U.S. academic procurement.
• Charles River Laboratories: Global CRO offering research animal models (including humanized mice), preclinical efficacy and toxicology services across oncology, neurology, and metabolic disease. Comparable end-to-end preclinical model + CRO platform, but at significantly larger scale and with broader geographic footprint.

Direct peers

• Biocytogen: China-based peer operating a similar humanized mouse catalog (RenMab/RenLite platforms) with heavy overlap to SMOC's U-HuDTMbase® in immune checkpoint and tumor target humanization. Direct competitor in therapeutic-target humanized mouse licensing and preclinical efficacy services.
• Taconic Biosciences: U.S.-based provider of genetically engineered mouse and rat models with custom model generation services. Closely comparable business model on the model generation side, including humanized and immunodeficient models for drug discovery.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/shanghai-model-organisms-center-usa-llc

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Shanghai Model Organisms Center (USA), LLC